알파셉트

알파셉트
알파셉트 구조식 이미지
카스 번호:
222535-22-0
한글명:
알파셉트
동의어(한글):
알파셉트
상품명:
alefacept
동의어(영문):
Lfa 3;Bg 9712;Bg 9273;Amevive;Lfa 3tip;Lfa 3cd2;Research Grade Alefacept;Human lfa 3igg fusion protein;Research Grade Alefacept (DHC20803);1-92-Lfa-3 (antigen) (human) fusion protein with immunoglobulin G1 (human hinge-ch2-ch3 gamma1-chain), dimer
CBNumber:
CB51390099
분자식:
포뮬러 무게:
0
MOL 파일:
Mol file

알파셉트 속성

물리적 상태
Liquid
색상
Colorless to light yellow

안전

알파셉트 C화학적 특성, 용도, 생산

개요

Alefacept is a recombinant human LFA3-Ig-G1 fusion protein that blocks the T-cell CD2 receptor preventing T-cell proliferation, a key mechanism in psoriasis. It was launched in the US for the treatment of chronic plaque psoriasis. It is a dimeric fusion protein consisting of the LFA-3 (leukocyte function antigen-3) and Fc (hinge, CH2 and CH3) portion of human IgG1 and has been produced in Chinese hamster ovary (CHO) and NS- 0 myeloma cell lines. In transgenic mice expressing human CD2, alefacept demonstrated efficacy in inhibiting antigen and mitogen-induced T-cell response. In the baboon cardiac-graft survival model alefacept, dosed 3 mpk intravenously for 12 days and treatment initiated two days before graft surgery, increased the mean survival of the transplanted hearts from 10.6 days (placebo) to 18.0 days (treatment group). In all clinical trials, improvement in PASI scores were noted and a long-lasting effect was noted. Thus this agent does not require chronic, maintenance dosing in all patients. Clinical studies for repeat courses (second twelve weeks) showed additional improvement. It has a half-life of 12 days, is dosed once weekly by injection either subcutaneously or intramuscularly and is approved for 12-week regimen. Side effects limit the use of current treatments such as phototherapy, cyclosporin, and methotrexate. Thus far, alefacept has been well tolerated.

용도

Treatment of plaque psoriasis.

Indications

Alefacept (Amevive) is a fully human lymphocyte function–associated antigen 3/immunoglobulin 1 (LFA-3/IgG1) fusion protein. It binds to CD2 on T cells, inhibiting T-cell activation and producing selective T-cell apoptosis. Alefacept is FDA approved as a 12-week course of 15 mg weekly intramuscular injections. Long remissions can be seen in responders. Peripheral CD4 counts should be followed and doses withheld if counts drop below 250 cells/μL. Therapy should be discontinued if the CD4 count remains below 250 cells/μL for >4 weeks. A second course lengthens the period of remission without additional toxicities.

알파셉트 준비 용품 및 원자재

원자재

준비 용품


알파셉트 공급 업체

글로벌( 14)공급 업체
공급자 전화 이메일 국가 제품 수 이점
Beijing HuaMeiHuLiBiological Chemical 010-56205725
waley188@sohu.com China 12335 58
Wuhan Chemstan Biotechnology Co., Ltd. 027-65317797 15926423062
422450190@qq.com China 10457 58
Biolab Reagents 027-65279366 18108604862
products@biolabreagent.com China 9818 58
Atagenix Laboratories 027-87008169 17762441161
info@atagenix.com China 9848 58
United States Biological --
sales@advtechind.com United States 6075 58

Copyright 2019 © ChemicalBook. All rights reserved